Recently, it has been shown that both complexes bindspecifically to human serum apotransferrin and the resulting adducts have been studiedthrough spectroscopic and chromatographic techniques with the ultimate goal of preparingadducts with good selectivity for cancer cells due to the fact that tumour cells express highamounts of transferrin receptors on their cell surface. The gene discussed is TFRC; the disease is cancer.